Global Opioid-Induced Constipation Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Opioid-Induced Constipation market size is predicted to grow from US$ 2707 million in 2025 to US$ 3581 million in 2031; it is expected to grow at a CAGR of 4.8% from 2025 to 2031.
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
LP Information, Inc. (LPI) ' newest research report, the “Opioid-Induced Constipation Industry Forecast” looks at past sales and reviews total world Opioid-Induced Constipation sales in 2024, providing a comprehensive analysis by region and market sector of projected Opioid-Induced Constipation sales for 2025 through 2031. With Opioid-Induced Constipation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Opioid-Induced Constipation industry.
This Insight Report provides a comprehensive analysis of the global Opioid-Induced Constipation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Opioid-Induced Constipation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Opioid-Induced Constipation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Opioid-Induced Constipation and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Opioid-Induced Constipation.
This report presents a comprehensive overview, market shares, and growth opportunities of Opioid-Induced Constipation market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Opioid-Induced Constipation market?
What factors are driving Opioid-Induced Constipation market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Opioid-Induced Constipation market opportunities vary by end market size?
How does Opioid-Induced Constipation break out by Type, by Application?
The global Opioid-Induced Constipation market size is predicted to grow from US$ 2707 million in 2025 to US$ 3581 million in 2031; it is expected to grow at a CAGR of 4.8% from 2025 to 2031.
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
LP Information, Inc. (LPI) ' newest research report, the “Opioid-Induced Constipation Industry Forecast” looks at past sales and reviews total world Opioid-Induced Constipation sales in 2024, providing a comprehensive analysis by region and market sector of projected Opioid-Induced Constipation sales for 2025 through 2031. With Opioid-Induced Constipation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Opioid-Induced Constipation industry.
This Insight Report provides a comprehensive analysis of the global Opioid-Induced Constipation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Opioid-Induced Constipation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Opioid-Induced Constipation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Opioid-Induced Constipation and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Opioid-Induced Constipation.
This report presents a comprehensive overview, market shares, and growth opportunities of Opioid-Induced Constipation market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Methylnaltrexone Bromide
- Lubiprostone
- Naloxegol
- Others
- Hospital
- Pharmacy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Takeda Pharmaceuticals
- Bayer
- Sanofi
- Mallinckrodt
- Salix (Bausch Health)
- AstraZeneca
- Progenics Pharmaceuticals
- Purdue Pharm
- Nektar Therapeutics
- Daiichi Sankyo
- Prestige
- GSK
- Shionogi
What is the 10-year outlook for the global Opioid-Induced Constipation market?
What factors are driving Opioid-Induced Constipation market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Opioid-Induced Constipation market opportunities vary by end market size?
How does Opioid-Induced Constipation break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Opioid-Induced Constipation Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Opioid-Induced Constipation by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Opioid-Induced Constipation by Country/Region, 2020, 2024 & 2031
2.2 Opioid-Induced Constipation Segment by Type
2.2.1 Methylnaltrexone Bromide
2.2.2 Lubiprostone
2.2.3 Naloxegol
2.2.4 Others
2.3 Opioid-Induced Constipation Sales by Type
2.3.1 Global Opioid-Induced Constipation Sales Market Share by Type (2020-2025)
2.3.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2020-2025)
2.3.3 Global Opioid-Induced Constipation Sale Price by Type (2020-2025)
2.4 Opioid-Induced Constipation Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Other
2.5 Opioid-Induced Constipation Sales by Application
2.5.1 Global Opioid-Induced Constipation Sale Market Share by Application (2020-2025)
2.5.2 Global Opioid-Induced Constipation Revenue and Market Share by Application (2020-2025)
2.5.3 Global Opioid-Induced Constipation Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Opioid-Induced Constipation Breakdown Data by Company
3.1.1 Global Opioid-Induced Constipation Annual Sales by Company (2020-2025)
3.1.2 Global Opioid-Induced Constipation Sales Market Share by Company (2020-2025)
3.2 Global Opioid-Induced Constipation Annual Revenue by Company (2020-2025)
3.2.1 Global Opioid-Induced Constipation Revenue by Company (2020-2025)
3.2.2 Global Opioid-Induced Constipation Revenue Market Share by Company (2020-2025)
3.3 Global Opioid-Induced Constipation Sale Price by Company
3.4 Key Manufacturers Opioid-Induced Constipation Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Opioid-Induced Constipation Product Location Distribution
3.4.2 Players Opioid-Induced Constipation Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR OPIOID-INDUCED CONSTIPATION BY GEOGRAPHIC REGION
4.1 World Historic Opioid-Induced Constipation Market Size by Geographic Region (2020-2025)
4.1.1 Global Opioid-Induced Constipation Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Opioid-Induced Constipation Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Opioid-Induced Constipation Market Size by Country/Region (2020-2025)
4.2.1 Global Opioid-Induced Constipation Annual Sales by Country/Region (2020-2025)
4.2.2 Global Opioid-Induced Constipation Annual Revenue by Country/Region (2020-2025)
4.3 Americas Opioid-Induced Constipation Sales Growth
4.4 APAC Opioid-Induced Constipation Sales Growth
4.5 Europe Opioid-Induced Constipation Sales Growth
4.6 Middle East & Africa Opioid-Induced Constipation Sales Growth
5 AMERICAS
5.1 Americas Opioid-Induced Constipation Sales by Country
5.1.1 Americas Opioid-Induced Constipation Sales by Country (2020-2025)
5.1.2 Americas Opioid-Induced Constipation Revenue by Country (2020-2025)
5.2 Americas Opioid-Induced Constipation Sales by Type (2020-2025)
5.3 Americas Opioid-Induced Constipation Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Opioid-Induced Constipation Sales by Region
6.1.1 APAC Opioid-Induced Constipation Sales by Region (2020-2025)
6.1.2 APAC Opioid-Induced Constipation Revenue by Region (2020-2025)
6.2 APAC Opioid-Induced Constipation Sales by Type (2020-2025)
6.3 APAC Opioid-Induced Constipation Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Opioid-Induced Constipation by Country
7.1.1 Europe Opioid-Induced Constipation Sales by Country (2020-2025)
7.1.2 Europe Opioid-Induced Constipation Revenue by Country (2020-2025)
7.2 Europe Opioid-Induced Constipation Sales by Type (2020-2025)
7.3 Europe Opioid-Induced Constipation Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Opioid-Induced Constipation by Country
8.1.1 Middle East & Africa Opioid-Induced Constipation Sales by Country (2020-2025)
8.1.2 Middle East & Africa Opioid-Induced Constipation Revenue by Country (2020-2025)
8.2 Middle East & Africa Opioid-Induced Constipation Sales by Type (2020-2025)
8.3 Middle East & Africa Opioid-Induced Constipation Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Opioid-Induced Constipation
10.3 Manufacturing Process Analysis of Opioid-Induced Constipation
10.4 Industry Chain Structure of Opioid-Induced Constipation
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Opioid-Induced Constipation Distributors
11.3 Opioid-Induced Constipation Customer
12 WORLD FORECAST REVIEW FOR OPIOID-INDUCED CONSTIPATION BY GEOGRAPHIC REGION
12.1 Global Opioid-Induced Constipation Market Size Forecast by Region
12.1.1 Global Opioid-Induced Constipation Forecast by Region (2026-2031)
12.1.2 Global Opioid-Induced Constipation Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Opioid-Induced Constipation Forecast by Type (2026-2031)
12.7 Global Opioid-Induced Constipation Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Takeda Pharmaceuticals
13.1.1 Takeda Pharmaceuticals Company Information
13.1.2 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolios and Specifications
13.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Takeda Pharmaceuticals Main Business Overview
13.1.5 Takeda Pharmaceuticals Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Opioid-Induced Constipation Product Portfolios and Specifications
13.2.3 Bayer Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Opioid-Induced Constipation Product Portfolios and Specifications
13.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Mallinckrodt
13.4.1 Mallinckrodt Company Information
13.4.2 Mallinckrodt Opioid-Induced Constipation Product Portfolios and Specifications
13.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Mallinckrodt Main Business Overview
13.4.5 Mallinckrodt Latest Developments
13.5 Salix (Bausch Health)
13.5.1 Salix (Bausch Health) Company Information
13.5.2 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolios and Specifications
13.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Salix (Bausch Health) Main Business Overview
13.5.5 Salix (Bausch Health) Latest Developments
13.6 AstraZeneca
13.6.1 AstraZeneca Company Information
13.6.2 AstraZeneca Opioid-Induced Constipation Product Portfolios and Specifications
13.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 AstraZeneca Main Business Overview
13.6.5 AstraZeneca Latest Developments
13.7 Progenics Pharmaceuticals
13.7.1 Progenics Pharmaceuticals Company Information
13.7.2 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolios and Specifications
13.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Progenics Pharmaceuticals Main Business Overview
13.7.5 Progenics Pharmaceuticals Latest Developments
13.8 Purdue Pharm
13.8.1 Purdue Pharm Company Information
13.8.2 Purdue Pharm Opioid-Induced Constipation Product Portfolios and Specifications
13.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Purdue Pharm Main Business Overview
13.8.5 Purdue Pharm Latest Developments
13.9 Nektar Therapeutics
13.9.1 Nektar Therapeutics Company Information
13.9.2 Nektar Therapeutics Opioid-Induced Constipation Product Portfolios and Specifications
13.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Nektar Therapeutics Main Business Overview
13.9.5 Nektar Therapeutics Latest Developments
13.10 Daiichi Sankyo
13.10.1 Daiichi Sankyo Company Information
13.10.2 Daiichi Sankyo Opioid-Induced Constipation Product Portfolios and Specifications
13.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Daiichi Sankyo Main Business Overview
13.10.5 Daiichi Sankyo Latest Developments
13.11 Prestige
13.11.1 Prestige Company Information
13.11.2 Prestige Opioid-Induced Constipation Product Portfolios and Specifications
13.11.3 Prestige Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Prestige Main Business Overview
13.11.5 Prestige Latest Developments
13.12 GSK
13.12.1 GSK Company Information
13.12.2 GSK Opioid-Induced Constipation Product Portfolios and Specifications
13.12.3 GSK Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 GSK Main Business Overview
13.12.5 GSK Latest Developments
13.13 Shionogi
13.13.1 Shionogi Company Information
13.13.2 Shionogi Opioid-Induced Constipation Product Portfolios and Specifications
13.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Shionogi Main Business Overview
13.13.5 Shionogi Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Opioid-Induced Constipation Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Opioid-Induced Constipation Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Methylnaltrexone Bromide
Table 4. Major Players of Lubiprostone
Table 5. Major Players of Naloxegol
Table 6. Major Players of Others
Table 7. Global Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)
Table 8. Global Opioid-Induced Constipation Sales Market Share byType (2020-2025)
Table 9. Global Opioid-Induced Constipation Revenue byType (2020-2025) & ($ million)
Table 10. Global Opioid-Induced Constipation Revenue Market Share byType (2020-2025)
Table 11. Global Opioid-Induced Constipation Sale Price byType (2020-2025) & (USD/Unit)
Table 12. Global Opioid-Induced Constipation Sale by Application (2020-2025) & (K Units)
Table 13. Global Opioid-Induced Constipation Sale Market Share by Application (2020-2025)
Table 14. Global Opioid-Induced Constipation Revenue by Application (2020-2025) & ($ million)
Table 15. Global Opioid-Induced Constipation Revenue Market Share by Application (2020-2025)
Table 16. Global Opioid-Induced Constipation Sale Price by Application (2020-2025) & (USD/Unit)
Table 17. Global Opioid-Induced Constipation Sales by Company (2020-2025) & (K Units)
Table 18. Global Opioid-Induced Constipation Sales Market Share by Company (2020-2025)
Table 19. Global Opioid-Induced Constipation Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Opioid-Induced Constipation Revenue Market Share by Company (2020-2025)
Table 21. Global Opioid-Induced Constipation Sale Price by Company (2020-2025) & (USD/Unit)
Table 22. Key Manufacturers Opioid-Induced Constipation Producing Area Distribution and Sales Area
Table 23. Players Opioid-Induced Constipation Products Offered
Table 24. Opioid-Induced Constipation Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Opioid-Induced Constipation Sales by Geographic Region (2020-2025) & (K Units)
Table 28. Global Opioid-Induced Constipation Sales Market Share Geographic Region (2020-2025)
Table 29. Global Opioid-Induced Constipation Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Opioid-Induced Constipation Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Opioid-Induced Constipation Sales by Country/Region (2020-2025) & (K Units)
Table 32. Global Opioid-Induced Constipation Sales Market Share by Country/Region (2020-2025)
Table 33. Global Opioid-Induced Constipation Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Opioid-Induced Constipation Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)
Table 36. Americas Opioid-Induced Constipation Sales Market Share by Country (2020-2025)
Table 37. Americas Opioid-Induced Constipation Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)
Table 39. Americas Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
Table 40. APAC Opioid-Induced Constipation Sales by Region (2020-2025) & (K Units)
Table 41. APAC Opioid-Induced Constipation Sales Market Share by Region (2020-2025)
Table 42. APAC Opioid-Induced Constipation Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)
Table 44. APAC Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
Table 45. Europe Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)
Table 46. Europe Opioid-Induced Constipation Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)
Table 48. Europe Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
Table 49. Middle East & Africa Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)
Table 50. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)
Table 52. Middle East & Africa Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Opioid-Induced Constipation
Table 54. Key Market Challenges & Risks of Opioid-Induced Constipation
Table 55. Key IndustryTrends of Opioid-Induced Constipation
Table 56. Opioid-Induced Constipation Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Opioid-Induced Constipation Distributors List
Table 59. Opioid-Induced Constipation Customer List
Table 60. Global Opioid-Induced Constipation SalesForecast by Region (2026-2031) & (K Units)
Table 61. Global Opioid-Induced Constipation RevenueForecast by Region (2026-2031) & ($ millions)
Table 62. Americas Opioid-Induced Constipation SalesForecast by Country (2026-2031) & (K Units)
Table 63. Americas Opioid-Induced Constipation Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 64. APAC Opioid-Induced Constipation SalesForecast by Region (2026-2031) & (K Units)
Table 65. APAC Opioid-Induced Constipation Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Europe Opioid-Induced Constipation SalesForecast by Country (2026-2031) & (K Units)
Table 67. Europe Opioid-Induced Constipation RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa Opioid-Induced Constipation SalesForecast by Country (2026-2031) & (K Units)
Table 69. Middle East & Africa Opioid-Induced Constipation RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Global Opioid-Induced Constipation SalesForecast byType (2026-2031) & (K Units)
Table 71. Global Opioid-Induced Constipation RevenueForecast byType (2026-2031) & ($ millions)
Table 72. Global Opioid-Induced Constipation SalesForecast by Application (2026-2031) & (K Units)
Table 73. Global Opioid-Induced Constipation RevenueForecast by Application (2026-2031) & ($ millions)
Table 74.Takeda Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 75.Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolios and Specifications
Table 76.Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77.Takeda Pharmaceuticals Main Business
Table 78.Takeda Pharmaceuticals Latest Developments
Table 79. Bayer Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 80. Bayer Opioid-Induced Constipation Product Portfolios and Specifications
Table 81. Bayer Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 82. Bayer Main Business
Table 83. Bayer Latest Developments
Table 84. Sanofi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 85. Sanofi Opioid-Induced Constipation Product Portfolios and Specifications
Table 86. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 87. Sanofi Main Business
Table 88. Sanofi Latest Developments
Table 89. Mallinckrodt Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 90. Mallinckrodt Opioid-Induced Constipation Product Portfolios and Specifications
Table 91. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 92. Mallinckrodt Main Business
Table 93. Mallinckrodt Latest Developments
Table 94. Salix (Bausch Health) Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 95. Salix (Bausch Health) Opioid-Induced Constipation Product Portfolios and Specifications
Table 96. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 97. Salix (Bausch Health) Main Business
Table 98. Salix (Bausch Health) Latest Developments
Table 99. AstraZeneca Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 100. AstraZeneca Opioid-Induced Constipation Product Portfolios and Specifications
Table 101. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 102. AstraZeneca Main Business
Table 103. AstraZeneca Latest Developments
Table 104. Progenics Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 105. Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolios and Specifications
Table 106. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 107. Progenics Pharmaceuticals Main Business
Table 108. Progenics Pharmaceuticals Latest Developments
Table 109. Purdue Pharm Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 110. Purdue Pharm Opioid-Induced Constipation Product Portfolios and Specifications
Table 111. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 112. Purdue Pharm Main Business
Table 113. Purdue Pharm Latest Developments
Table 114. NektarTherapeutics Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 115. NektarTherapeutics Opioid-Induced Constipation Product Portfolios and Specifications
Table 116. NektarTherapeutics Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 117. NektarTherapeutics Main Business
Table 118. NektarTherapeutics Latest Developments
Table 119. Daiichi Sankyo Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 120. Daiichi Sankyo Opioid-Induced Constipation Product Portfolios and Specifications
Table 121. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 122. Daiichi Sankyo Main Business
Table 123. Daiichi Sankyo Latest Developments
Table 124. Prestige Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 125. Prestige Opioid-Induced Constipation Product Portfolios and Specifications
Table 126. Prestige Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 127. Prestige Main Business
Table 128. Prestige Latest Developments
Table 129. GSK Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 130. GSK Opioid-Induced Constipation Product Portfolios and Specifications
Table 131. GSK Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 132. GSK Main Business
Table 133. GSK Latest Developments
Table 134. Shionogi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 135. Shionogi Opioid-Induced Constipation Product Portfolios and Specifications
Table 136. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 137. Shionogi Main Business
Table 138. Shionogi Latest Developments
LIST OFFIGURES
Figure 1. Picture of Opioid-Induced Constipation
Figure 2. Opioid-Induced Constipation Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Opioid-Induced Constipation Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Opioid-Induced Constipation Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Opioid-Induced Constipation Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Opioid-Induced Constipation Sales Market Share by Country/Region (2024)
Figure 10. Opioid-Induced Constipation Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Methylnaltrexone Bromide
Figure 12. Product Picture of Lubiprostone
Figure 13. Product Picture of Naloxegol
Figure 14. Product Picture of Others
Figure 15. Global Opioid-Induced Constipation Sales Market Share byType in 2025
Figure 16. Global Opioid-Induced Constipation Revenue Market Share byType (2020-2025)
Figure 17. Opioid-Induced Constipation Consumed in Hospital
Figure 18. Global Opioid-Induced Constipation Market: Hospital (2020-2025) & (K Units)
Figure 19. Opioid-Induced Constipation Consumed in Pharmacy
Figure 20. Global Opioid-Induced Constipation Market: Pharmacy (2020-2025) & (K Units)
Figure 21. Opioid-Induced Constipation Consumed in Other
Figure 22. Global Opioid-Induced Constipation Market: Other (2020-2025) & (K Units)
Figure 23. Global Opioid-Induced Constipation Sale Market Share by Application (2024)
Figure 24. Global Opioid-Induced Constipation Revenue Market Share by Application in 2025
Figure 25. Opioid-Induced Constipation Sales by Company in 2025 (K Units)
Figure 26. Global Opioid-Induced Constipation Sales Market Share by Company in 2025
Figure 27. Opioid-Induced Constipation Revenue by Company in 2025 ($ millions)
Figure 28. Global Opioid-Induced Constipation Revenue Market Share by Company in 2025
Figure 29. Global Opioid-Induced Constipation Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Opioid-Induced Constipation Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Opioid-Induced Constipation Sales 2020-2025 (K Units)
Figure 32. Americas Opioid-Induced Constipation Revenue 2020-2025 ($ millions)
Figure 33. APAC Opioid-Induced Constipation Sales 2020-2025 (K Units)
Figure 34. APAC Opioid-Induced Constipation Revenue 2020-2025 ($ millions)
Figure 35. Europe Opioid-Induced Constipation Sales 2020-2025 (K Units)
Figure 36. Europe Opioid-Induced Constipation Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Opioid-Induced Constipation Sales 2020-2025 (K Units)
Figure 38. Middle East & Africa Opioid-Induced Constipation Revenue 2020-2025 ($ millions)
Figure 39. Americas Opioid-Induced Constipation Sales Market Share by Country in 2025
Figure 40. Americas Opioid-Induced Constipation Revenue Market Share by Country (2020-2025)
Figure 41. Americas Opioid-Induced Constipation Sales Market Share byType (2020-2025)
Figure 42. Americas Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
Figure 43. United States Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Opioid-Induced Constipation Sales Market Share by Region in 2025
Figure 48. APAC Opioid-Induced Constipation Revenue Market Share by Region (2020-2025)
Figure 49. APAC Opioid-Induced Constipation Sales Market Share byType (2020-2025)
Figure 50. APAC Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
Figure 51. China Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 55. India Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 57. ChinaTaiwan Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Opioid-Induced Constipation Sales Market Share by Country in 2025
Figure 59. Europe Opioid-Induced Constipation Revenue Market Share by Country (2020-2025)
Figure 60. Europe Opioid-Induced Constipation Sales Market Share byType (2020-2025)
Figure 61. Europe Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
Figure 62. Germany Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 63.France Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Opioid-Induced Constipation Sales Market Share byType (2020-2025)
Figure 69. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
Figure 70. Egypt Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 73.Turkey Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Opioid-Induced Constipation in 2025
Figure 76. Manufacturing Process Analysis of Opioid-Induced Constipation
Figure 77. Industry Chain Structure of Opioid-Induced Constipation
Figure 78. Channels of Distribution
Figure 79. Global Opioid-Induced Constipation Sales MarketForecast by Region (2026-2031)
Figure 80. Global Opioid-Induced Constipation Revenue Market ShareForecast by Region (2026-2031)
Figure 81. Global Opioid-Induced Constipation Sales Market ShareForecast byType (2026-2031)
Figure 82. Global Opioid-Induced Constipation Revenue Market ShareForecast byType (2026-2031)
Figure 83. Global Opioid-Induced Constipation Sales Market ShareForecast by Application (2026-2031)
Figure 84. Global Opioid-Induced Constipation Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Opioid-Induced Constipation Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Opioid-Induced Constipation by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Opioid-Induced Constipation by Country/Region, 2020, 2024 & 2031
2.2 Opioid-Induced Constipation Segment by Type
2.2.1 Methylnaltrexone Bromide
2.2.2 Lubiprostone
2.2.3 Naloxegol
2.2.4 Others
2.3 Opioid-Induced Constipation Sales by Type
2.3.1 Global Opioid-Induced Constipation Sales Market Share by Type (2020-2025)
2.3.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2020-2025)
2.3.3 Global Opioid-Induced Constipation Sale Price by Type (2020-2025)
2.4 Opioid-Induced Constipation Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Other
2.5 Opioid-Induced Constipation Sales by Application
2.5.1 Global Opioid-Induced Constipation Sale Market Share by Application (2020-2025)
2.5.2 Global Opioid-Induced Constipation Revenue and Market Share by Application (2020-2025)
2.5.3 Global Opioid-Induced Constipation Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Opioid-Induced Constipation Breakdown Data by Company
3.1.1 Global Opioid-Induced Constipation Annual Sales by Company (2020-2025)
3.1.2 Global Opioid-Induced Constipation Sales Market Share by Company (2020-2025)
3.2 Global Opioid-Induced Constipation Annual Revenue by Company (2020-2025)
3.2.1 Global Opioid-Induced Constipation Revenue by Company (2020-2025)
3.2.2 Global Opioid-Induced Constipation Revenue Market Share by Company (2020-2025)
3.3 Global Opioid-Induced Constipation Sale Price by Company
3.4 Key Manufacturers Opioid-Induced Constipation Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Opioid-Induced Constipation Product Location Distribution
3.4.2 Players Opioid-Induced Constipation Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR OPIOID-INDUCED CONSTIPATION BY GEOGRAPHIC REGION
4.1 World Historic Opioid-Induced Constipation Market Size by Geographic Region (2020-2025)
4.1.1 Global Opioid-Induced Constipation Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Opioid-Induced Constipation Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Opioid-Induced Constipation Market Size by Country/Region (2020-2025)
4.2.1 Global Opioid-Induced Constipation Annual Sales by Country/Region (2020-2025)
4.2.2 Global Opioid-Induced Constipation Annual Revenue by Country/Region (2020-2025)
4.3 Americas Opioid-Induced Constipation Sales Growth
4.4 APAC Opioid-Induced Constipation Sales Growth
4.5 Europe Opioid-Induced Constipation Sales Growth
4.6 Middle East & Africa Opioid-Induced Constipation Sales Growth
5 AMERICAS
5.1 Americas Opioid-Induced Constipation Sales by Country
5.1.1 Americas Opioid-Induced Constipation Sales by Country (2020-2025)
5.1.2 Americas Opioid-Induced Constipation Revenue by Country (2020-2025)
5.2 Americas Opioid-Induced Constipation Sales by Type (2020-2025)
5.3 Americas Opioid-Induced Constipation Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Opioid-Induced Constipation Sales by Region
6.1.1 APAC Opioid-Induced Constipation Sales by Region (2020-2025)
6.1.2 APAC Opioid-Induced Constipation Revenue by Region (2020-2025)
6.2 APAC Opioid-Induced Constipation Sales by Type (2020-2025)
6.3 APAC Opioid-Induced Constipation Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Opioid-Induced Constipation by Country
7.1.1 Europe Opioid-Induced Constipation Sales by Country (2020-2025)
7.1.2 Europe Opioid-Induced Constipation Revenue by Country (2020-2025)
7.2 Europe Opioid-Induced Constipation Sales by Type (2020-2025)
7.3 Europe Opioid-Induced Constipation Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Opioid-Induced Constipation by Country
8.1.1 Middle East & Africa Opioid-Induced Constipation Sales by Country (2020-2025)
8.1.2 Middle East & Africa Opioid-Induced Constipation Revenue by Country (2020-2025)
8.2 Middle East & Africa Opioid-Induced Constipation Sales by Type (2020-2025)
8.3 Middle East & Africa Opioid-Induced Constipation Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Opioid-Induced Constipation
10.3 Manufacturing Process Analysis of Opioid-Induced Constipation
10.4 Industry Chain Structure of Opioid-Induced Constipation
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Opioid-Induced Constipation Distributors
11.3 Opioid-Induced Constipation Customer
12 WORLD FORECAST REVIEW FOR OPIOID-INDUCED CONSTIPATION BY GEOGRAPHIC REGION
12.1 Global Opioid-Induced Constipation Market Size Forecast by Region
12.1.1 Global Opioid-Induced Constipation Forecast by Region (2026-2031)
12.1.2 Global Opioid-Induced Constipation Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Opioid-Induced Constipation Forecast by Type (2026-2031)
12.7 Global Opioid-Induced Constipation Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Takeda Pharmaceuticals
13.1.1 Takeda Pharmaceuticals Company Information
13.1.2 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolios and Specifications
13.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Takeda Pharmaceuticals Main Business Overview
13.1.5 Takeda Pharmaceuticals Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Opioid-Induced Constipation Product Portfolios and Specifications
13.2.3 Bayer Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Opioid-Induced Constipation Product Portfolios and Specifications
13.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Mallinckrodt
13.4.1 Mallinckrodt Company Information
13.4.2 Mallinckrodt Opioid-Induced Constipation Product Portfolios and Specifications
13.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Mallinckrodt Main Business Overview
13.4.5 Mallinckrodt Latest Developments
13.5 Salix (Bausch Health)
13.5.1 Salix (Bausch Health) Company Information
13.5.2 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolios and Specifications
13.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Salix (Bausch Health) Main Business Overview
13.5.5 Salix (Bausch Health) Latest Developments
13.6 AstraZeneca
13.6.1 AstraZeneca Company Information
13.6.2 AstraZeneca Opioid-Induced Constipation Product Portfolios and Specifications
13.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 AstraZeneca Main Business Overview
13.6.5 AstraZeneca Latest Developments
13.7 Progenics Pharmaceuticals
13.7.1 Progenics Pharmaceuticals Company Information
13.7.2 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolios and Specifications
13.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Progenics Pharmaceuticals Main Business Overview
13.7.5 Progenics Pharmaceuticals Latest Developments
13.8 Purdue Pharm
13.8.1 Purdue Pharm Company Information
13.8.2 Purdue Pharm Opioid-Induced Constipation Product Portfolios and Specifications
13.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Purdue Pharm Main Business Overview
13.8.5 Purdue Pharm Latest Developments
13.9 Nektar Therapeutics
13.9.1 Nektar Therapeutics Company Information
13.9.2 Nektar Therapeutics Opioid-Induced Constipation Product Portfolios and Specifications
13.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Nektar Therapeutics Main Business Overview
13.9.5 Nektar Therapeutics Latest Developments
13.10 Daiichi Sankyo
13.10.1 Daiichi Sankyo Company Information
13.10.2 Daiichi Sankyo Opioid-Induced Constipation Product Portfolios and Specifications
13.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Daiichi Sankyo Main Business Overview
13.10.5 Daiichi Sankyo Latest Developments
13.11 Prestige
13.11.1 Prestige Company Information
13.11.2 Prestige Opioid-Induced Constipation Product Portfolios and Specifications
13.11.3 Prestige Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Prestige Main Business Overview
13.11.5 Prestige Latest Developments
13.12 GSK
13.12.1 GSK Company Information
13.12.2 GSK Opioid-Induced Constipation Product Portfolios and Specifications
13.12.3 GSK Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 GSK Main Business Overview
13.12.5 GSK Latest Developments
13.13 Shionogi
13.13.1 Shionogi Company Information
13.13.2 Shionogi Opioid-Induced Constipation Product Portfolios and Specifications
13.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Shionogi Main Business Overview
13.13.5 Shionogi Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Opioid-Induced Constipation Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Opioid-Induced Constipation Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Methylnaltrexone Bromide
Table 4. Major Players of Lubiprostone
Table 5. Major Players of Naloxegol
Table 6. Major Players of Others
Table 7. Global Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)
Table 8. Global Opioid-Induced Constipation Sales Market Share byType (2020-2025)
Table 9. Global Opioid-Induced Constipation Revenue byType (2020-2025) & ($ million)
Table 10. Global Opioid-Induced Constipation Revenue Market Share byType (2020-2025)
Table 11. Global Opioid-Induced Constipation Sale Price byType (2020-2025) & (USD/Unit)
Table 12. Global Opioid-Induced Constipation Sale by Application (2020-2025) & (K Units)
Table 13. Global Opioid-Induced Constipation Sale Market Share by Application (2020-2025)
Table 14. Global Opioid-Induced Constipation Revenue by Application (2020-2025) & ($ million)
Table 15. Global Opioid-Induced Constipation Revenue Market Share by Application (2020-2025)
Table 16. Global Opioid-Induced Constipation Sale Price by Application (2020-2025) & (USD/Unit)
Table 17. Global Opioid-Induced Constipation Sales by Company (2020-2025) & (K Units)
Table 18. Global Opioid-Induced Constipation Sales Market Share by Company (2020-2025)
Table 19. Global Opioid-Induced Constipation Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Opioid-Induced Constipation Revenue Market Share by Company (2020-2025)
Table 21. Global Opioid-Induced Constipation Sale Price by Company (2020-2025) & (USD/Unit)
Table 22. Key Manufacturers Opioid-Induced Constipation Producing Area Distribution and Sales Area
Table 23. Players Opioid-Induced Constipation Products Offered
Table 24. Opioid-Induced Constipation Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Opioid-Induced Constipation Sales by Geographic Region (2020-2025) & (K Units)
Table 28. Global Opioid-Induced Constipation Sales Market Share Geographic Region (2020-2025)
Table 29. Global Opioid-Induced Constipation Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Opioid-Induced Constipation Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Opioid-Induced Constipation Sales by Country/Region (2020-2025) & (K Units)
Table 32. Global Opioid-Induced Constipation Sales Market Share by Country/Region (2020-2025)
Table 33. Global Opioid-Induced Constipation Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Opioid-Induced Constipation Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)
Table 36. Americas Opioid-Induced Constipation Sales Market Share by Country (2020-2025)
Table 37. Americas Opioid-Induced Constipation Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)
Table 39. Americas Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
Table 40. APAC Opioid-Induced Constipation Sales by Region (2020-2025) & (K Units)
Table 41. APAC Opioid-Induced Constipation Sales Market Share by Region (2020-2025)
Table 42. APAC Opioid-Induced Constipation Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)
Table 44. APAC Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
Table 45. Europe Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)
Table 46. Europe Opioid-Induced Constipation Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)
Table 48. Europe Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
Table 49. Middle East & Africa Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)
Table 50. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Opioid-Induced Constipation Sales byType (2020-2025) & (K Units)
Table 52. Middle East & Africa Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Opioid-Induced Constipation
Table 54. Key Market Challenges & Risks of Opioid-Induced Constipation
Table 55. Key IndustryTrends of Opioid-Induced Constipation
Table 56. Opioid-Induced Constipation Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Opioid-Induced Constipation Distributors List
Table 59. Opioid-Induced Constipation Customer List
Table 60. Global Opioid-Induced Constipation SalesForecast by Region (2026-2031) & (K Units)
Table 61. Global Opioid-Induced Constipation RevenueForecast by Region (2026-2031) & ($ millions)
Table 62. Americas Opioid-Induced Constipation SalesForecast by Country (2026-2031) & (K Units)
Table 63. Americas Opioid-Induced Constipation Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 64. APAC Opioid-Induced Constipation SalesForecast by Region (2026-2031) & (K Units)
Table 65. APAC Opioid-Induced Constipation Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Europe Opioid-Induced Constipation SalesForecast by Country (2026-2031) & (K Units)
Table 67. Europe Opioid-Induced Constipation RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa Opioid-Induced Constipation SalesForecast by Country (2026-2031) & (K Units)
Table 69. Middle East & Africa Opioid-Induced Constipation RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Global Opioid-Induced Constipation SalesForecast byType (2026-2031) & (K Units)
Table 71. Global Opioid-Induced Constipation RevenueForecast byType (2026-2031) & ($ millions)
Table 72. Global Opioid-Induced Constipation SalesForecast by Application (2026-2031) & (K Units)
Table 73. Global Opioid-Induced Constipation RevenueForecast by Application (2026-2031) & ($ millions)
Table 74.Takeda Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 75.Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolios and Specifications
Table 76.Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 77.Takeda Pharmaceuticals Main Business
Table 78.Takeda Pharmaceuticals Latest Developments
Table 79. Bayer Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 80. Bayer Opioid-Induced Constipation Product Portfolios and Specifications
Table 81. Bayer Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 82. Bayer Main Business
Table 83. Bayer Latest Developments
Table 84. Sanofi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 85. Sanofi Opioid-Induced Constipation Product Portfolios and Specifications
Table 86. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 87. Sanofi Main Business
Table 88. Sanofi Latest Developments
Table 89. Mallinckrodt Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 90. Mallinckrodt Opioid-Induced Constipation Product Portfolios and Specifications
Table 91. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 92. Mallinckrodt Main Business
Table 93. Mallinckrodt Latest Developments
Table 94. Salix (Bausch Health) Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 95. Salix (Bausch Health) Opioid-Induced Constipation Product Portfolios and Specifications
Table 96. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 97. Salix (Bausch Health) Main Business
Table 98. Salix (Bausch Health) Latest Developments
Table 99. AstraZeneca Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 100. AstraZeneca Opioid-Induced Constipation Product Portfolios and Specifications
Table 101. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 102. AstraZeneca Main Business
Table 103. AstraZeneca Latest Developments
Table 104. Progenics Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 105. Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolios and Specifications
Table 106. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 107. Progenics Pharmaceuticals Main Business
Table 108. Progenics Pharmaceuticals Latest Developments
Table 109. Purdue Pharm Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 110. Purdue Pharm Opioid-Induced Constipation Product Portfolios and Specifications
Table 111. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 112. Purdue Pharm Main Business
Table 113. Purdue Pharm Latest Developments
Table 114. NektarTherapeutics Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 115. NektarTherapeutics Opioid-Induced Constipation Product Portfolios and Specifications
Table 116. NektarTherapeutics Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 117. NektarTherapeutics Main Business
Table 118. NektarTherapeutics Latest Developments
Table 119. Daiichi Sankyo Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 120. Daiichi Sankyo Opioid-Induced Constipation Product Portfolios and Specifications
Table 121. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 122. Daiichi Sankyo Main Business
Table 123. Daiichi Sankyo Latest Developments
Table 124. Prestige Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 125. Prestige Opioid-Induced Constipation Product Portfolios and Specifications
Table 126. Prestige Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 127. Prestige Main Business
Table 128. Prestige Latest Developments
Table 129. GSK Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 130. GSK Opioid-Induced Constipation Product Portfolios and Specifications
Table 131. GSK Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 132. GSK Main Business
Table 133. GSK Latest Developments
Table 134. Shionogi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 135. Shionogi Opioid-Induced Constipation Product Portfolios and Specifications
Table 136. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 137. Shionogi Main Business
Table 138. Shionogi Latest Developments
LIST OFFIGURES
Figure 1. Picture of Opioid-Induced Constipation
Figure 2. Opioid-Induced Constipation Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Opioid-Induced Constipation Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Opioid-Induced Constipation Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Opioid-Induced Constipation Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Opioid-Induced Constipation Sales Market Share by Country/Region (2024)
Figure 10. Opioid-Induced Constipation Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Methylnaltrexone Bromide
Figure 12. Product Picture of Lubiprostone
Figure 13. Product Picture of Naloxegol
Figure 14. Product Picture of Others
Figure 15. Global Opioid-Induced Constipation Sales Market Share byType in 2025
Figure 16. Global Opioid-Induced Constipation Revenue Market Share byType (2020-2025)
Figure 17. Opioid-Induced Constipation Consumed in Hospital
Figure 18. Global Opioid-Induced Constipation Market: Hospital (2020-2025) & (K Units)
Figure 19. Opioid-Induced Constipation Consumed in Pharmacy
Figure 20. Global Opioid-Induced Constipation Market: Pharmacy (2020-2025) & (K Units)
Figure 21. Opioid-Induced Constipation Consumed in Other
Figure 22. Global Opioid-Induced Constipation Market: Other (2020-2025) & (K Units)
Figure 23. Global Opioid-Induced Constipation Sale Market Share by Application (2024)
Figure 24. Global Opioid-Induced Constipation Revenue Market Share by Application in 2025
Figure 25. Opioid-Induced Constipation Sales by Company in 2025 (K Units)
Figure 26. Global Opioid-Induced Constipation Sales Market Share by Company in 2025
Figure 27. Opioid-Induced Constipation Revenue by Company in 2025 ($ millions)
Figure 28. Global Opioid-Induced Constipation Revenue Market Share by Company in 2025
Figure 29. Global Opioid-Induced Constipation Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Opioid-Induced Constipation Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Opioid-Induced Constipation Sales 2020-2025 (K Units)
Figure 32. Americas Opioid-Induced Constipation Revenue 2020-2025 ($ millions)
Figure 33. APAC Opioid-Induced Constipation Sales 2020-2025 (K Units)
Figure 34. APAC Opioid-Induced Constipation Revenue 2020-2025 ($ millions)
Figure 35. Europe Opioid-Induced Constipation Sales 2020-2025 (K Units)
Figure 36. Europe Opioid-Induced Constipation Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Opioid-Induced Constipation Sales 2020-2025 (K Units)
Figure 38. Middle East & Africa Opioid-Induced Constipation Revenue 2020-2025 ($ millions)
Figure 39. Americas Opioid-Induced Constipation Sales Market Share by Country in 2025
Figure 40. Americas Opioid-Induced Constipation Revenue Market Share by Country (2020-2025)
Figure 41. Americas Opioid-Induced Constipation Sales Market Share byType (2020-2025)
Figure 42. Americas Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
Figure 43. United States Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Opioid-Induced Constipation Sales Market Share by Region in 2025
Figure 48. APAC Opioid-Induced Constipation Revenue Market Share by Region (2020-2025)
Figure 49. APAC Opioid-Induced Constipation Sales Market Share byType (2020-2025)
Figure 50. APAC Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
Figure 51. China Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 55. India Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 57. ChinaTaiwan Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Opioid-Induced Constipation Sales Market Share by Country in 2025
Figure 59. Europe Opioid-Induced Constipation Revenue Market Share by Country (2020-2025)
Figure 60. Europe Opioid-Induced Constipation Sales Market Share byType (2020-2025)
Figure 61. Europe Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
Figure 62. Germany Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 63.France Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Opioid-Induced Constipation Sales Market Share byType (2020-2025)
Figure 69. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
Figure 70. Egypt Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 73.Turkey Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Opioid-Induced Constipation Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Opioid-Induced Constipation in 2025
Figure 76. Manufacturing Process Analysis of Opioid-Induced Constipation
Figure 77. Industry Chain Structure of Opioid-Induced Constipation
Figure 78. Channels of Distribution
Figure 79. Global Opioid-Induced Constipation Sales MarketForecast by Region (2026-2031)
Figure 80. Global Opioid-Induced Constipation Revenue Market ShareForecast by Region (2026-2031)
Figure 81. Global Opioid-Induced Constipation Sales Market ShareForecast byType (2026-2031)
Figure 82. Global Opioid-Induced Constipation Revenue Market ShareForecast byType (2026-2031)
Figure 83. Global Opioid-Induced Constipation Sales Market ShareForecast by Application (2026-2031)
Figure 84. Global Opioid-Induced Constipation Revenue Market ShareForecast by Application (2026-2031)
More Publications
Global Opioid Induced Constipation (OIC) Drug Market Growth 2025-2031
US$ 3,660.00
October 2025
134 pages
